Ultragenyx (RARE) CEO gets new RSUs, options and shifts 400K shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. President & CEO Emil D. Kakkis reported new equity compensation awards and updated indirect holdings. He received 76,745 Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan, which vest in four equal annual installments from the grant date.
He was also granted a stock option for 132,693 shares of common stock at an exercise price of $24.52 per share, vesting 25% on the first anniversary of the grant and the remainder monthly thereafter until 2036-04-16. Following these awards, he directly holds 735,739 shares of common stock.
The filing also reflects updated indirect ownership, including 1,758,985 shares held through the Emil Kakkis and Jenny Soriano Living Trust and an aggregate 400,000 shares contributed to two grantor retained annuity trusts (GRATs). These changes reflect compensation grants and estate-planning transfers rather than open-market trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
KAKKIS EMIL D
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 132,693 | $0.00 | -- |
| Grant/Award | Common Stock | 76,745 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 132,693 shares (Direct, null);
Common Stock — 735,739 shares (Direct, null);
Common Stock — 1,758,985 shares (Indirect, By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909)
Footnotes (1)
- Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT"). On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Key Figures
RSU grant size: 76,745 shares
Stock option grant: 132,693 shares
Option exercise price: $24.52/share
+5 more
8 metrics
RSU grant size
76,745 shares
RSUs under 2023 Incentive Plan, vest over four years
Stock option grant
132,693 shares
Option on common stock granted to CEO
Option exercise price
$24.52/share
Strike price for 132,693-share stock option
Option expiration
2036-04-16
Expiration date of new stock option grant
Direct common shares
735,739 shares
Common stock directly held after reported awards
Living trust holdings
1,758,985 shares
Common stock held by Emil Kakkis and Jenny Soriano Living Trust
GRAT contribution
400,000 shares
Aggregate shares contributed to two grantor retained annuity trusts
GRAT holdings entry
200,000 shares
Per GRAT holding shown, two such entries reported
Key Terms
Restricted Stock Units ("RSUs"), 2023 Incentive Plan, grantor retained annuity trusts, Stock Option (Right to Buy), +1 more
5 terms
Restricted Stock Units ("RSUs") financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2023 Incentive Plan financial
"Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan."
grantor retained annuity trusts financial
"contribution of an aggregate of 400,000 shares previously owned indirectly ... to two grantor retained annuity trusts"
A grantor retained annuity trust (GRAT) is an estate-planning tool where an owner transfers assets into a trust and receives fixed payments back for a set number of years; any remaining assets after that period pass to designated beneficiaries. For investors it matters because it can move future investment growth to heirs while potentially reducing gift and estate taxes — like putting a rising asset in a timed box that pays you first and gives the remaining upside to others.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with 132,693.0000 shares"
beneficially owned financial
"Amount of securities beneficially owned following reported transaction reflects the contribution"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What equity awards did Ultragenyx (RARE) CEO Emil Kakkis receive?
Emil Kakkis received 76,745 RSUs and a stock option for 132,693 shares at $24.52 per share. These awards are compensation grants under Ultragenyx’s 2023 Incentive Plan, with multi-year vesting rather than immediate cash transactions.
How do the new RSUs for Ultragenyx (RARE) CEO vest over time?
The 76,745 RSUs granted to Emil Kakkis vest in four equal annual installments. One quarter of the underlying shares vests on each anniversary of the grant date, so the RSUs become fully vested on the fourth anniversary of the grant.
What are the terms of Emil Kakkis’s new Ultragenyx stock option?
The new stock option covers 132,693 shares of common stock at an exercise price of $24.52 per share. Twenty-five percent vests on the first anniversary of the grant, then 1/48 vests monthly until expiration on 2036-04-16.
What indirect Ultragenyx holdings are reported for Emil Kakkis?
The filing shows 1,758,985 shares of Ultragenyx held through the Emil Kakkis and Jenny Soriano Living Trust. It also notes an aggregate 400,000 shares contributed to two grantor retained annuity trusts (GRATs) as part of indirect beneficial ownership.
Did the Ultragenyx (RARE) CEO’s Form 4 show any open-market stock sales or purchases?
The Form 4 highlights equity awards and estate-planning transfers, not open-market trades. It reports RSU and stock option grants plus contributions of 400,000 shares to two GRATs, with no buy or sell transactions coded as open-market activity.